This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2003 Remove Healthcare Remove Pharmaceutical research Remove Side effects
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.

Food and Drug Administration 74
Food and Drug Administration Safety Patients Leads 74
article thumbnail

Beating the Big C

Pharmaceutical Technology

JULY 23, 2008

” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.” “There’s a huge clinical need which has been undelivered for years,” says Gustav Ando, manager of the healthcare business development unit [HBDU] at Global Insight. We’re on the right path.”

Side effects 52
Side effects Marketing Pharmaceutical Sales 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024